Patient Preferences for Attributes of Biologic Treatments in Moderate to Severe Asthma: A Discrete Choice Experiment Study
Min Yang,Jingdong Chao,Mirko Fillbrunn,Usha G Mallya,Min-Jung Wang,Leigh Franke,Lauren Cohn,Siddhesh Kamat
DOI: https://doi.org/10.2147/PPA.S365117
2022-09-23
Patient Preference and Adherence
Abstract:Min Yang, 1 Jingdong Chao, 2 Mirko Fillbrunn, 1 Usha G Mallya, 3 Min-Jung Wang, 1 Leigh Franke, 1 Lauren Cohn, 4, 5 Siddhesh Kamat 2 1 Analysis Group, Inc, Boston, MA, USA; 2 Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA; 3 Sanofi, Boston, MA, USA; 4 Section of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA; 5 VA Connecticut Healthcare System, West Haven, CT, USA Correspondence: Min Yang, Analysis Group, Inc, 111 Huntington Avenue, Fourteenth Floor, Boston, MA, 02199, USA, Tel +1-617-425-8487, Fax +1-617-425-8001, Email Purpose: Multiple biologics are available for moderate to severe asthma. Given the important relationship between patient engagement in healthcare decision-making and health outcomes, patient preference is an increasingly important consideration. This study elicited patients' preferences for attributes of biologic therapies for moderate to severe asthma. Patient and Methods: A discrete choice experiment (DCE) questionnaire was designed to collect data from an existing survey panel of adults with moderate to severe asthma in the United States. Patients were asked to select their preferred hypothetical treatment from profiles with varying attributes related to efficacy, safety, and administration convenience. Conditional logit regression models were used to quantify patient preferences. Results: Of 301 eligible patients who completed the survey, the mean age was 46.7± 15.1 years and 71.8% were female. Patients had asthma for 22.5± 16.3 years on average, and most (97.3%) had experienced ≥ 1 asthma attack in the past 12 months. Among treatment attributes examined, patients most valued the absence of a black box warning for the risk of a life-threatening allergic reaction, effectiveness of reducing severe asthma exacerbations, and improvement in lung function (all p < 0.001). Home administration setting for subcutaneous injections (vs doctor's office/clinic) (p = 0.009) and ability of a biologic to treat additional chronic condition(s) (p < 0.05) were also considered important. Dosing frequency and type of injection device were not significant factors. Conclusion: Patients with moderate to severe asthma valued efficacy and safety over convenience attributes when selecting biologic treatments. Awareness of these preferences can facilitate patient-physician shared decision-making when managing moderate to severe asthma in clinical practice. Keywords: asthma, patient preference, biologic, treatment Asthma is a common, chronic respiratory disease, affecting millions of people in the United States (US). Patients with moderate to severe asthma may experience frequent respiratory symptoms and exacerbations, reversible airflow obstruction, bronchial hyper-responsiveness, and airway inflammation which, if not well-controlled, can lead to substantial morbidity, impaired health-related quality of life, and potentially asthma-related mortality. 1–3 The majority (~70%) of patients with moderate to severe asthma have Type 2 inflammation that is often characterized by eosinophilia, increased fractional concentration of exhaled nitric oxide, or allergen-driven asthma. 4–7 Inhaled corticosteroids (ICS), long-acting beta agonists (LABA), and leukotriene-modifying agents are the standard of care for the treatment of moderate to severe asthma. However, many patients still fail to have sustained symptom control, and long-term use of systemic corticosteroids is associated with harmful side effects. 8,9 With the availability of biologic therapies that specifically target antibodies, inflammatory molecules, or cell receptors, the clinical management of patients with moderate to severe asthma who are inadequately controlled on ICS + additional controllers has substantially improved. 4 As of 2022, six biologics have been approved by the US Food and Drug Administration (FDA) for patients with severe or uncontrolled asthma, and the majority of these medications are delivered via subcutaneous injection. 10 These biologics include anti-immunoglobulin E therapy (omalizumab) and inhibitors of interleukin 5 (IL-5; mepolizumab and reslizumab), the IL-5 receptor (benralizumab), the IL-4 receptor (dupilumab), and thymic stromal lymphpoietin (tezepelumab). With the increasing number of treatment options available, an appreciation of treatment preferences from the patient perspective can improve patient engagement and inform patient-physician shared decision-making. The Global Initiative For Asthma (GINA) 4 emphasizes the importance of patient preferences during a clinical evaluation, because it has -Abstract Truncated-
medicine, general & internal